Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. (Q34088608)

30 July 2017

1 reference

title

Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. (English)

1 reference

30 July 2017

Kast RE

1

1 reference

30 July 2017

1 November 2000

1 reference

International Journal of Immunopharmacology

30 July 2017

1 reference

30 July 2017

22

1 reference

30 July 2017

11

1 reference

30 July 2017

1001-1006

1 reference

Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Pathophysiologic alterations induced by tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Joint inflammation and cartilage destruction may occur uncoupled

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

TNF modulates endothelial properties by decreasing cAMP

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Pulmonary edema induced by phorbol myristate acetate is attenuated by compounds that increase intracellular cAMP

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Signal transduction pathways involved in the synergistic stimulation of prostaglandin production by interleukin-1beta and tumor necrosis factor alpha in human gingival fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Tumor necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Review article: non-steroidal anti-inflammatory drug-induced gastrointestinal permeability

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Crohn's disease remission with phenelzine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Molecular mechanisms of antiasthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Theophylline in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Cellular and molecular mechanisms involved in insulin's potentiation of glycogen synthase activity by metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900046-1

7 January 2021

10.1016/S0192-0561(00)00046-1

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11090708